List view / Grid view

Anti-Cancer Therapeutics

Imfinzi^™ plus chemotherapy triples small cell lung cancer survival

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.

news

EMA’s human medicines committee (CHMP) September meeting highlights

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.

news

Kisqali^® demonstrates longest overall median breast cancer survival

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

Kisqali plus letrozole achieved a median overall survival of over five years, the longest ever reported for HR+/HER2 breast cancer.

Doctor with mammograph, indicating breast cancer

news

Trodelvy^® improves breast cancer survival and quality of life

17 September 2021 | By Anna Begley (European Pharmaceutical Review)

Trodelvy significantly improved overall survival and demonstrated clinically meaningful improvements in quality of life in Phase III study.

news

Sotorasib plus panitumumab shows efficacy against colorectal cancer

17 September 2021 | By Anna Begley (European Pharmaceutical Review)

Sotorasib combined with panitumumab displayed 27 percent response rate against colorectal cancer in Phase I/II trial.

news

Mobocertinib approved as first oral therapy for EGFR Exon20+ NSCLC

16 September 2021 | By Anna Begley (European Pharmaceutical Review)

FDA approves mobocertinib as the first oral therapy for patients with non-small cell lung cancer with EGFR Exon20 insertion mutations.

news

Opdivo^® and Yervoy^® combo increases mesothelioma survival

15 September 2021 | By Anna Begley (European Pharmaceutical Review)

Opdivo and Yervoy displayed a 23 percent survival rate at three years compared to 15 percent with chemotherapy, Phase III trial shows.

news

Novartis submit BLA for tislelizumab for oesophageal cancer treatment

15 September 2021 | By Anna Begley (European Pharmaceutical Review)

US FDA have accepted Biologics License Application (BLA) for tislelizumab for the treatment of oesophageal squamous cell carcinoma cancer.

news

Neoadjuvant atezolizumab combination meets safety criteria in pleural mesothelioma

13 September 2021 | By Anna Begley (European Pharmaceutical Review)

Neoadjuvant cisplatin and pemetrexed in combination with atezolizumab met safety criteria in resectable pleural mesothelioma clinical study.

news

Erleada^® reduces prostate-specific antigen (PSA) by 86 percent

13 September 2021 | By Anna Begley (European Pharmaceutical Review)

Erleada achieved an 86 percent reduction in PSA at 12 months in the majority of patients, shows post-hoc analysis of Phase III study.

news

Melflufen increases refractory multiple myeloma survival in Phase III study

13 September 2021 | By Anna Begley (European Pharmaceutical Review)

Melfufen met the primary endpoint of superior progression free survival (PFS) with a median of 6.8 months in Phase III OCEAN trial.

news

Imfinzi^™ and tremelimumab combo improves NSCLC outcomes

10 September 2021 | By Anna Begley (European Pharmaceutical Review)

Imfinizi™ and tremelimumab in combination with chemotherapy improved non-small lung cancer (NSCLC) survival by 23 percent in a Phase III study.

Pleural fluid cytology of lung (pulmonary) papillary adenocarcinoma

news

Lumakras^™ (sotorasib) helps control brain metastases

10 September 2021 | By Anna Begley (European Pharmaceutical Review)

Amgen’s Lumakras™, a KRAS inhibitor, was found to improve the stability of brain metastases in a Phase II study.

Photomicrograph of diffuse B-cell lymphoma

news

Minjuvi^® receives EC approval to treat large B-cell lymphoma

27 August 2021 | By Anna Begley (European Pharmaceutical Review)

European Commission (EC) approves Minjuvi with lenalidomide for the treatment of large B-cell lymphoma in adults.

Business people shaking hands behind technology images

news

Pfizer to acquire Trillium immuno-oncology therapeutics

24 August 2021 | By Anna Begley (European Pharmaceutical Review)

Pfizer will acquire Trillium Therapeutics, an immuno-oncology company, potentially enhancing growth of cancer treatments from 2026.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Anti-Cancer Therapeutics